EDEN PRAIRIE, Minn., May 11, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its fiscal second quarter 2023 ended March 31, 2023 and provide a corporate update on May 11, 2023 at 4:30 PM Eastern Time.
Conference Call and Webcast Information:
Thursday, May 11, 2023 – 4:30 PM Eastern Time
Participant Dial-In:
888-645-4404 / 862-298-0702
Live Webcast:
Join here.
Phone Replay:
877-660-6853 / 201-612-7415, Access ID: 13738525; available through May 25, 2023
Webcast Replay:
Available for 12 months
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit nmtc1.com.
Contact:
800-631-4030
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.74 |
Daily Change: | 0.02 3.26 |
Daily Volume: | 204,375 |
Market Cap: | US$37.200M |
August 18, 2025 July 23, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load